| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 338,341 | 297,304 | ||
| Short-term investments | 1,901,830 | 1,992,676 | ||
| Contracts receivable | 24,608 | 52,580 | ||
| Inventories | 10,470 | 8,481 | ||
| Other current assets | 243,744 | 226,109 | ||
| Total current assets | 2,518,993 | 2,577,150 | ||
| Property, plant and equipment, net | 106,117 | 111,951 | ||
| Right-of-use assets | 241,993 | 163,933 | ||
| Deposits and other assets | 165,988 | 132,099 | ||
| Total assets | 3,033,091 | 2,985,133 | ||
| Accounts payable | 14,326 | 22,800 | ||
| Accrued compensation | 57,019 | 46,564 | ||
| Accrued liabilities | 99,310 | 98,957 | ||
| Income taxes payable | 101 | 81 | ||
| 0 percent convertible senior notes, net | 630,911 | 630,118 | ||
| Current portion of deferred contract revenue | 76,986 | 75,910 | ||
| Other current liabilities | 24,803 | 22,806 | ||
| Total current liabilities | 903,456 | 897,236 | ||
| Long-term deferred contract revenue | 107,906 | 125,095 | ||
| Convertible senior notes, net-Convertible Senior Notes175Percent | 567,123 | 566,420 | ||
| Convertible senior notes, net-Convertible Senior Notes0Percent | 0 | 0 | ||
| Liability related to sale of future royalties, net | 545,182 | 541,205 | ||
| Long-term lease liabilities | 262,672 | 164,379 | ||
| Long-term obligations | 28,785 | 59,074 | ||
| Total liabilities | 2,415,124 | 2,353,409 | ||
| Common stock, 0.001 par value 300,000,000 shares authorized, 161,137,930 and 157,908,815 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 161 | 159 | ||
| Additional paid-in capital | 3,045,585 | 2,932,747 | ||
| Accumulated other comprehensive income | -25,978 | -27,987 | ||
| Accumulated deficit | -2,401,801 | -2,273,195 | ||
| Total stockholders' equity | 617,967 | 631,724 | ||
| Total liabilities and stockholders equity | 3,033,091 | 2,985,133 | ||
IONIS PHARMACEUTICALS INC (IONS)
IONIS PHARMACEUTICALS INC (IONS)